A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Vyepti, eptinezumab-jjmr
Synonyms :
eptinezumab
Class :
CGRP Monoclonal Antibodies; Antimigraine Agents
Brand Name :
Vyepti, eptinezumab-jjmr
Synonyms :
eptinezumab
Class :
CGRP Monoclonal Antibodies; Antimigraine Agents
Dosage forms & Strengths:
Adult:
Solution for Injection
100 mg/ml
100 mg intravenously every 3 months
In some patients, the dose can be increased to 300 mg
Safety and efficacy are not seen in pediatrics
Safety and efficacy are not seen in pediatrics
measles, mumps, rubella, and varicella vaccine, live (Rx)
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
measles mumps and rubella vaccine, live
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
smallpox (vaccinia) vaccine, live
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
respiratory syncytial virus vaccine, adjuvanted
may decrease the therapeutic effect when combined with Vaccines
respiratory syncytial virus (RSV) vaccine
may decrease the therapeutic effect when combined with Vaccines
poliovirus vaccine, live, trivalent
may decrease the therapeutic effect when combined with Vaccines
poliovirus vaccine inactivated
may decrease the therapeutic effect when combined with Vaccines
respiratory syncytial virus vaccine, adjuvanted
may decrease the therapeutic effect when combined with Vaccines
respiratory syncytial virus (RSV) vaccine
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may increase the risk of adverse effects when combined
it increases the adverse effects caused due to eptinezumab
it increases the adverse effects caused due to eptinezumab
it increases the adverse effects caused due to eptinezumab
it increases the adverse effects caused due to eptinezumab
it increases the adverse effects caused due to eptinezumab
it increases the effect of thrombogenesis of eptinezumab
it increases the effect of thrombogenesis of eptinezumab
it increases the adverse effects caused due to eptinezumab
it increases the adverse effects caused due to eptinezumab
it increases the adverse effects caused due to eptinezumab
it increases the adverse effects caused due to eptinezumab
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
may reduce the therapeutic effect of immune checkpoint inhibitors
it may enhance the adverse effects when combined with aducanumab
may increase the risk or severity of adverse effects when combined
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
measles, mumps, rubella, and varicella vaccine, live (Rx)
immune globulins decrease the efficacy of live vaccines
measles mumps and rubella vaccine, live
immune globulins decrease the efficacy of live vaccines
immune globulins decrease the efficacy of live vaccines
smallpox (vaccinia) vaccine, live
immune globulins decrease the efficacy of live vaccines
immune globulins decrease the efficacy of live vaccines
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
bazedoxifene/conjugated estrogens
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
may have an increased thrombogenic effect when combined with anthrax immune globulin
may have an increased thrombogenic effect when combined with anthrax immune globulin
an increase in CNS depression may be seen
cinnarizine and dimenhydrinateÂ
this combination will make you feel sleepy or tired when Analgesics used in combination
Actions and Spectrum:
eptinezumab is a monoclonal antibody medication that is used to prevent migraines. It works by binding to a protein called calcitonin gene-related peptide (CGRP), which is responsible for migraines.
1-10%:
Hypersensitivity (1-2%)
Nasopharyngitis (6-8%)
Black Box Warning:
It is essential to follow the dosage and administration instructions for the medication carefully.
Contraindication/Caution:
eptinezumab should not be used in people hypersensitive to the drug itself.
Pregnancy consideration:
No data is available regarding the usage of the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the secretion of the drug in breast milk.
Pregnancy category:
Pharmacology
eptinezumab is a monoclonal antibody designed to bind to calcitonin gene-related peptide (CGRP), a protein that plays a role in the development of migraines. The binding of eptinezumab to CGRP prevents it from activating its receptors and thereby reduces the frequency of migraines. eptinezumab is a humanized monoclonal antibody that is produced using recombinant DNA technology. It is administered as an IV infusion and is designed to have a long-lasting effect, with a dosing schedule every 3 months.
Pharmacodynamics:
eptinezumab binds to calcitonin gene-related peptide (CGRP), a protein. It is a monoclonal antibody. By binding to CGRP, eptinezumab blocks its activity and reduces the frequency of migraines.
Pharmacokinetics:
Pharmacokinetics studies how a drug is absorbed, distributed, metabolized, and eliminated by the body. The pharmacokinetics of eptinezumab can be described by the following parameters.
Absorption
Peak plasma concentration is achieved steadily with every 3 monthly dose regimes.
Distribution
The volume of distribution is around 3.7L.
Metabolism
Proteolytic enzymes metabolize it into smaller peptides and amino acids.
Elimination and excretion
The half-life of the drug is 27 days.
The rate of clearance is 0.003 L/hr.
Administration:
The drug is compatible with 0.9% NaCl. To prepare the IV fluid:
Dilute the dosage in 100 ml of 0.9% NaCl
Gently dilute the components by inverting
Do not shake
Patient information leaflet
Generic Name: eptinezumab
Pronounced: ep-teen-zoo-mab
Why do we use eptinezumab?
eptinezumab is used to treat migraine.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
